Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …

Background: There is insufficient real-world data on the current status of Japanese patients
with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban …

Abstract Background The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized
8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary …

Background Standard treatment for venous thromboembolism (VTE) consists of a heparin
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …

The effectiveness and safety of acute venous thromboembolism (VTE) treatment with
rivaroxaban, demonstrated in phase-III trials, needs to be confirmed in daily care. To confirm …

We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Background Deep vein thrombosis (DVT) and pulmonary embolism are collectively known
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …

Background This study aimed to provide safety and efficacy data of rivaroxaban in routine
patient care in a non-selected symptomatic venous thromboembolism (VTE) population …

Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, is approved for the initial treatment
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …